Company Overview - Shenzhen Libang Precision Instrument Co., Ltd. operates in the biomedical industry, with a focus on ultrasound and in vitro diagnostics [2] - The company relocated to a new facility in Pingshan, Shenzhen, covering approximately 40,000 square meters, to enhance operational efficiency and employee stability [2] Financial Performance - In Q1 2018, the company reported total revenue of CNY 269.75 million, a year-on-year increase of 15.60% [3] - Net profit attributable to shareholders was CNY 36.82 million, up 43.94% year-on-year, driven by market opportunities and increased operational efficiency [3] R&D Investment - R&D expenditure for 2018 was CNY 178 million, representing 17.92% of total revenue, with a 0.66% increase from the previous year [3] - The company is focusing on ultrasound and in vitro diagnostics, with a dedicated R&D center in Silicon Valley [3] Sales System Adjustments - The domestic sales system underwent significant reforms in 2018, integrating internal and external sales teams to improve overall efficiency [4] - The sales team consists of over 600 members, with approximately 100 in external sales and 400-500 in internal sales [4] Product Development and Market Strategy - The company aims to expand its POCT (Point of Care Testing) platforms, particularly in obstetrics and other critical care areas [4] - In 2018, the company sold around 3.5 million blood gas test cards, with a target of 5 million for the current year [4] International Market Performance - In 2018, overseas revenue accounted for 57.33%, with North America contributing less than 10% [4] - The European market is expected to maintain steady growth, contributing about one-third of total foreign sales [4] Profitability and Cost Management - The company aims to maintain a profit growth rate in 2019 that exceeds the previous year's performance, with a focus on cost control and budget management [5] - The overall gross margin in 2018 was 54.60%, lower than competitors due to scale and product line maturity [6] Government Subsidies - The company received significant government subsidies in 2018, which are expected to decrease in 2019 but will still support R&D expenses [5] Competitive Landscape - The company faces competition in the ultrasound market, where it aims to enhance its brand influence and product offerings to gain market share [5] - The impact of the US-China trade war on pricing and margins is being managed through shared cost burdens with distributors [5]

Group 1: Company Overview and Investor Relations - The company, Shenzhen Libang Precision Instrument Co., Ltd., held an investor relations activity on May 16, 2018, including a site visit and product demonstration [1][2][3]. Group 2: Financial Performance - In 2017, the company achieved a revenue of 843 million CNY, representing a year-on-year growth of 20.81% [3][4]. - Domestic sales accounted for 352 million CNY, which is 41.78% of total revenue, with a growth of 32.62% year-on-year [3]. - The in-vitro diagnostic (IVD) product line revenue reached 80.11 million CNY, marking a significant increase of 56.87% year-on-year [6][7]. - In Q1 2018, the company reported a revenue of 233 million CNY, a year-on-year increase of 17.05% [4]. Group 3: Strategic Developments - In October 2017, the company acquired 100% of Sulis Healthcare Products Ltd., now known as Edan Medical (UK) Limited, to expand its direct sales activities in Europe [5]. - The subsidiary, Smart Health, generated a revenue of 7.21 million CNY in 2017, with a positive cash flow, indicating significant operational improvement [6]. Group 4: Market Trends and Opportunities - The global POCT (Point-of-Care Testing) market is expected to grow at a compound annual growth rate (CAGR) of approximately 8%, potentially reaching 24 billion USD in three years [6]. - The company has been increasing its investment in POCT research and development since 2009, with a strategic focus on expanding its product offerings [7]. Group 5: Challenges and Management Focus - In 2017, the company faced challenges with external sales, achieving 491 million CNY in foreign sales, impacted by significant currency depreciation [8]. - The company incurred a foreign exchange loss of 27.29 million CNY due to international market fluctuations [8]. - Management plans to enhance internal controls and cost management to improve operational efficiency and profitability [9].

Group 1: Financial Performance - The company's revenue for 2020 increased by 104.6%, while net profit grew by 395.37%, indicating a significant disparity between revenue and profit growth rates [6] - The first quarter of 2021 is crucial, with a target revenue of between 550 million to 600 million RMB, as the second quarter is not expected to match the exceptional sales figures of the previous year [4] - The company aims to maintain or slightly increase sales compared to the previous year, focusing on delivering satisfactory results to shareholders [3] Group 2: Market and Sales Strategy - The demand for non-epidemic products in overseas markets is gradually recovering, with customer orders returning to normal levels [3] - The company has established a comprehensive risk management mechanism to address the impact of exchange rate fluctuations on exports [3] - The company plans to expand its domestic market efforts while continuing to monitor and adjust strategies based on international market conditions [3] Group 3: Product Development and Innovation - The new blood gas testing product, i20, is expected to be launched within the next two years, with production capacity projected to reach 6 to 8 million units this year [4] - The company is focusing on developing innovative ultrasound products that incorporate advanced technologies like AI to address clinical needs [6] - Continuous investment in R&D is emphasized, with plans for future product development and potential acquisitions to enhance market presence [5] Group 4: Corporate Governance and Shareholder Relations - The company has a stable shareholding structure and has not received any acquisition offers recently, ensuring robust corporate governance [2] - Management acknowledges the current stock price is undervalued compared to the company's capabilities and market position [8] - The company is committed to enhancing communication with institutional investors to improve market perception and shareholder value [8] Group 5: Regulatory and Compliance - The company is currently undergoing clinical trials for its magnetic-sensitive immune detection tumor markers, with progress being monitored [7] - Recent changes in tax regulations regarding R&D expenses are expected to positively impact the company's net profit, although specific amounts will be determined post-audit [7]

1 证券代码：300206 证券简称：理邦仪器 编号：2021-001 深圳市理邦精密仪器股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------------|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | □特定对象调研 □分析师会议 | | 投资者关 | □媒体采访 | □业绩说明会 | | 系活动类 别 | □新闻发布会 □路演活动 | | | | □现场参观 | ...

1 证券代码：300206 证券简称：理邦仪器 编号：2021-002 深圳市理邦精密仪器股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | □特定对象调研 □分析师会议 | | 投资者关 | □媒体采访 | □业绩说明会 | | 系活动类 别 | □新闻发布会 □路演活动 | | | | □现场参观 | ■其他 电话会议 | | | | ...

东吴证券、深圳国银资本、九泰基金、明亚基金、福建匹克投资、Greencourt 碧云资本、新华资产、上汽颀臻（上海）资产管理、Oasis 绿洲资本、广东恒昇 基金、招银理财、北京齐济合创投资、WillingCap、展博投资、太平基金、中信 参与单位 保诚基金、菁英时代、长城基金、兴银理财、长盛基金、强英投资、前海开源基 名称及人 金、国联人寿、NTF Asset 新同方资管、川财证券、上海允文资产管理、深圳宏 员姓名 鼎财富管理、民生证券、国海资管、富安达基金、博远基金、福建鑫诺嘉誉投资、 杭州羲和资产管理、上海复杉投资管理、时代麦伯(厦门)企业管理、太平基金、 海通资管、睿扬投资、合正普惠投资、深圳探索投资俱乐部、一塔资本、上海聚 鸣投资管理、中信证券、其他个人投资者 投资者关 一、2021 年上半年经营情况介绍： 系活动主 2021 年上半年，公司预计实现营业收入 86,873.39 万元-91,983.59 万元， 要内容介 同比下降 28%-32%；预计实现归属于上市公司股东的净利润为 17,493.47 万元 绍 -19,857.46 万元，同比下降 58%-63%；预计实现扣除非经常性损益的净利润 ...

东吴证券、华安证券、德邦证券、银华基金、华夏久盈基金、大成基金、汇添富 基金、华富基金、大宇资本、泰聚资本、辰翔投资、通用投资、碧云资本、兴业 基金、国联安、中欧基金、中加基金、上海磐耀资产、东吴国际、象舆行投资、 参与单位 招商证券自营、中信保诚、民生医药、深圳前海铭鼎资产、深圳正德泰投资、凯 名称及人 石基金、上银基金、华宝基金、蜂巢基金、兴业基金、创金合信基金、东吴基金、 员姓名 中金基金、国融基金、长盛基金、Blackrock、前海天成时代、第一北京& First Manhattan、环懿投资、深圳思加资本、华泰自营、西部利得、格林基金、北京 九颂山河投资基金、凯石基金、恒越基金、深圳正德泰投资、平安养老、中泰资 管、浦银安盛、东证资管、深圳大道至诚投资、天治基金、融通基金、华泰柏瑞 其证券代码：300206 证券简称：理邦仪器 编号：2022-001 深圳市理邦精密仪器股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-------------|-------------|---------------------------|-------| | | | ■ ...

Group 1: Financial Performance - In the first half of 2022, the company experienced a growth in Q2 performance due to three main factors: reduced impact of foreign pandemic, recovery in procurement demand from medical institutions, and new product launches in ultrasound and maternal-child health sectors [1] - The revenue from the in vitro diagnostic product line reached 248 million yuan in 2021, primarily driven by blood gas products [2] - The company aims for a 50-60% growth in sales of pelvic floor products in 2022, with 30 million yuan in sales expected in 2021 [3] Group 2: Market Challenges - The company anticipates challenges in maintaining Q2 growth in Q3 and Q4 due to strict domestic pandemic controls and geopolitical factors affecting overseas business [2] - The ongoing domestic pandemic may delay project delivery timelines and reduce demand for monitoring and blood gas products compared to previous years [2] Group 3: Product Development and Strategy - The company is expanding its in vitro diagnostic business, with plans to launch a new generation of blood gas analyzers (i20) in Q4 2022 for overseas markets, and in 2023 for domestic use [2] - The pelvic floor product line is in its early stages, with plans to enhance competitiveness through portable home devices [3] - The company is focusing on expanding its ultrasound product line, which has seen rapid growth due to increased global marketing efforts and the release of pent-up demand post-pandemic [3] Group 4: Industry Trends and Opportunities - The company views the implementation of centralized procurement in the IVD industry as an opportunity to increase market share, particularly in the blood gas product segment, which currently has a market size of approximately 2.4 billion yuan, dominated by foreign brands [3] - The impact of new medical infrastructure investments on company performance is acknowledged, although specific contributions cannot be quantified due to varying investment levels across provinces [4]

Group 1: Financial Performance - The company achieved a revenue of 281 million CNY in the first half of 2022, a year-on-year decrease of approximately 20% compared to the previous year [2] - The net profit for the second quarter of 2022 reached 100 million CNY, indicating a significant recovery in operations [3] - The monitoring business, as a core segment, aims to stabilize or slightly increase its revenue compared to last year's total of 599 million CNY [5] Group 2: Business Growth and Strategy - The company expects the wave of new medical infrastructure investments to last for at least 3-5 years, focusing on both hard and soft investments [3] - The five-year strategic plan targets over 5 billion CNY in sales by 2025, with specific revenue goals for different product lines [4] - The ultrasound product line saw a revenue increase of approximately 30% year-on-year, driven by sustained R&D investment and expanded global marketing channels [4] Group 3: Market Dynamics and Challenges - The blood gas market is estimated to be around 4 billion USD globally, with the domestic market valued at over 2 billion CNY, indicating significant growth potential for local manufacturers [6] - The company faces challenges from global economic downturns and geopolitical conflicts, which may impact overall performance [5] - The impact of "volume-based procurement" policies is expected to be more pronounced in the medical device distribution sector, potentially benefiting companies with core competitive advantages [8]

Financial Performance - The company's revenue for Q3 2022 was CNY 383,997,814.73, representing a 2.08% increase year-on-year, while the year-to-date revenue decreased by 1.77% to CNY 1,241,682,027.20[4] - Net profit attributable to shareholders for Q3 2022 was CNY 39,306,511.87, a decrease of 40.25% compared to the same period last year, and year-to-date net profit decreased by 24.35% to CNY 189,735,741.06[4] - The basic earnings per share for Q3 2022 was CNY 0.0676, down 40.41% year-on-year, with diluted earnings per share also at CNY 0.0676[4] - In the first three quarters of 2022, the company achieved revenue of CNY 1,241.68 million, a year-on-year decrease of 1.77%[17] - The net profit attributable to shareholders for the same period was CNY 189.74 million, down 24.35% year-on-year[17] - Total operating revenue for Q3 2022 was CNY 1,241,682,027.20, a decrease of 1.3% compared to CNY 1,264,049,872.13 in Q3 2021[24] - Net profit for Q3 2022 was CNY 188,577,923.54, down 24.2% from CNY 248,602,011.37 in Q3 2021[25] Cash Flow - The net cash flow from operating activities for the year-to-date period was CNY 98,139,816.77, a significant decrease of 49.44% compared to the previous year[12] - The net cash flow from operating activities was 98,139,816.77 CNY, a decrease of 49.5% compared to 194,111,890.50 CNY in the previous year[28] - The cash flow from operating activities totaled 1,306,919,352.25 CNY, an increase from 1,273,784,483.05 CNY year-over-year[28] - The total cash inflow from investment activities was 504,986,433.70 CNY, down 33.1% from 756,881,664.39 CNY year-over-year[28] - The net cash flow from investment activities was -126,541,115.79 CNY, compared to -17,220,929.06 CNY in the same period last year[28] - The net cash flow from financing activities was -190,833,375.63 CNY, a decrease of 40.6% from -321,490,730.44 CNY year-over-year[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,020,151,537.21, a decrease of 1.37% from the end of the previous year[4] - Cash and cash equivalents as of September 30, 2022, were CNY 529.95 million, down from CNY 733.91 million at the beginning of the year[20] - Total assets as of September 30, 2022, amounted to CNY 2,020.15 million, a decrease from CNY 2,048.11 million at the start of the year[21] - The company's current liabilities totaled CNY 196.72 million, down from CNY 284.06 million at the beginning of the year[21] - The total liabilities amounted to CNY 220,183,220.56, down from CNY 316,226,496.70 year-over-year[25] Expenses - The company's financial expenses decreased by 1541.83% year-on-year, primarily due to exchange rate fluctuations[10] - R&D expenses increased by 17.86% year-on-year, while sales expenses rose by 14.95%[17] - Total operating costs increased to CNY 1,092,270,292.18, up 4.0% from CNY 1,049,810,570.88 in the previous year[24] Business Segments - The patient monitoring business saw a year-on-year decline of approximately 20%, but this was a significant improvement from a nearly 60% decline in 2021[17] - The ultrasound imaging business experienced a growth rate exceeding 30% year-on-year[17] Strategic Plans - The company plans to increase investment in R&D and market expansion to address challenges in the international political and economic landscape[17]